MRUS 241220 40.00P (MRUS241220P40000) Stock Options, News & Quotes

US OptionsDetailed Quotes

MRUS241220P40000

Watchlist

1.10
+0.50+83.33%

15min DelayClose Nov 21 15:59 ET

1.10High0.88Low

Intraday

5D
Daily

News

This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Benzinga13:25 ET
Pyxis Stock Craters 46% Amid Phase 1 Data, William Blair Downgrade
Seeking AlphaNov 21 10:20 ET
Goldman Sachs Initiates Merus(MRUS.US) With Buy Rating, Announces Target Price $73
Moomoo NewsNov 20 17:31 ET · Ratings
Merus Initiated With a Buy at Goldman Sachs
TipRanksNov 20 16:45 ET · Ratings
Needham Maintains Merus(MRUS.US) With Buy Rating, Maintains Target Price $85
Moomoo NewsNov 20 07:31 ET · Ratings
Truist Financial Initiates Merus(MRUS.US) With Buy Rating
Moomoo NewsNov 20 07:31 ET · Ratings

Comments

TrendTrader

May 24 13:26

Nice recovery. Scaling in

$Merus (MRUS.US)$

frankinglily

Apr 1 03:50

Updated Complete & Utter M&A Guesses Purely for Entertainment Purposes:

$SPDR S&P Biotech ETF (XBI.US)$
$Merck & Co (MRK.US)$ x $Immunovant (IMVT.US)$
$Eli Lilly and Co (LLY.US)$ x $Cytokinetics (CYTK.US)$ (and soon)
$Regeneron Pharmaceuticals (REGN.US)$ x $Apellis Pharmaceuticals (APLS.US)$ (panache & brash)
$Gilead Sciences (GILD.US)$ x % $Madrigal Pharmaceuticals (MDGL.US)$ (liver king)
$Bristol-Myers Squibb (BMY.US)$ x $Iovance Biotherapeutics (IOVA.US)$ (cell Tx boost needed)
$Eli Lilly and Co (LLY.US)$ x $Merus (MRUS.US)$ (partner n...

Moomoo AI

Jan 9 05:10

Merus' high P/S ratio is worrisome due to underwhelming revenue forecasts. The company's declining revenue growth and below-industry growth predictions may cause a drop in the P/S ratio, risking shareholders' investments.

There's Reason For Concern Over Merus N.V.'s (NASDAQ:MRUS) Massive 39% Price Jump

Analysts Notebook

Dec 27, 2023 04:18

Columns Biotech Outlook 2024: Analysts Believe the Biotech Sector is Poised for Recovery Next Year

Following a turbulent period, there has been a notable change in the trajectory of biotech stocks. After experiencing significant downturns in 2021 and 2022, the $SPDR S&P Biotech ETF (XBI.US)$ has seen an increase of 5.5% in the current year. However, it continues to trail considerably behind the $S&P 500 Index (.SPX.US)$, which has achieved a 24% gain. However, analysts indicate that the previously cool sent...

71504759

Jan 7, 2021 23:19

$Merus (MRUS.US)$ 71.55% is institutions owned, don't sell for cheap, at least 30.

Stocks & Markets Analysis